Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

Abstract

AbstractPatients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis. Their outcome in the post‐ponatinib era remains unclear. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Patients were divided into CP, AP, or blastic phase (BP) at the time of mutation detection. Overall survival (OS) was defined from the time of mutation detection to the date of death or last follow‐up. We identified a total of 107 patients: 54 (51%) in CP, 14 (13%) in AP, and 39 (36%) in BP. One hundred and two patients received subsequent therapy after the T315I mutation was detected. At a median follow‐up of 75 months (95% CI, 41–110), the median OS was 49 months (95% CI, 26–73) and the 5‐year OS rate was 44%. Patients who were in CML‐CP at the time of mutation detection had better survival compared with those in AP or BP, with a median OS of 132, 31, and 6 months, and 5‐year OS rates of 70%, 37%, and 10%, respectively (p < .001). Patients with CML‐CP treated with ponatinib and/or asciminib had a 5‐year OS of 77% compared with 50% in those who received other treatments (chemotherapy, second‐generation tyrosine kinase inhibitors, homoharringtonine, and investigational drugs) (p = .14). In summary, patients with CML‐CP at the time of T315I mutation detection may have a relatively indolent disease course with a long‐term OS of 70%. Treatment with third‐generation tyrosine kinase inhibitors seemed to improve survival in patients with CML‐CP.